-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, StsGtR6USaU6kX8WNj1cJt7QxCQSqEomAhKCZDoixW0ee9IceJx/XfYzWeBvnZde x64gsTxZcoNVWWWF8PAeMg== 0001144204-11-010511.txt : 20110223 0001144204-11-010511.hdr.sgml : 20110223 20110223165430 ACCESSION NUMBER: 0001144204-11-010511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110216 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20110223 DATE AS OF CHANGE: 20110223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WaferGen Bio-systems, Inc. CENTRAL INDEX KEY: 0001368993 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 900416683 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53252 FILM NUMBER: 11632848 BUSINESS ADDRESS: STREET 1: 7400 PASEO PADRE PARKWAY CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: (510) 651-4450 MAIL ADDRESS: STREET 1: 7400 PASEO PADRE PARKWAY CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: La Burbuja Cafe, Inc. DATE OF NAME CHANGE: 20060714 8-K 1 v212368_8-k.htm Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): February 16, 2011
 
WaferGen Bio-systems, Inc.
(Exact name of registrant as specified in its charter)
 
Nevada
  
333-136424
  
90-0416683
(State or other jurisdiction
  
(Commission
  
(I.R.S. Employer
of incorporation)
  
File Number)
  
Identification No.)
         
 
7400 Paseo Padre Parkway
Fremont, CA
  
 
 
94555
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (510) 651-4450
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
*   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
*    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
* Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
* Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 16, 2011, the Compensation Committee (the “Committee”) of the Board of Directors of WaferGen Bio-systems, Inc. (the “Company”) approved the Company’s cash bonus plan for fiscal year 2011 for the Company’s officers, including its named executive officers.
 
Each named executive officer has been assigned a target bonus percentage of such officer’s current base salary ranging between 35% and 60% per individual. Each individual’s actual bonus will be determined by a formula based on the achievement of certain specified corporate goals established by the Company’s Board of Directors with respect to fiscal year 2011 (“Company Objectives”), as well as annual individual goals (“Individual Objectives”), except for the Company’s Chief Executive Officer, whose bonus will be based solely on the achievement of the Company Objectives. Bonuses for all other individuals are based on weighting of between 60% and 90% for Company Objectives and between 10% and 40% for Individual Objectives.
 
Bonus payments are anticipated to be made yearly.  The Committee determines the actual bonus payments for all of the named executive officers.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
WaferGen Bio-systems, Inc.
 
Date: February 23, 2011
By:
/s/ Alnoor Shivji
   
Alnoor Shivji
   
Chairman, President and Chief Executive Officer

 
 
 
-----END PRIVACY-ENHANCED MESSAGE-----